SCHEMBL6997036

SCHEMBL6997036

Cc1sc(Br)c(C(=O)Nc2ccccc2O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
LMNA P02545 4/20 0.47
HTT P42858 4/20 0.47
TP53 P04637 3/20 0.47
GAA P10253 3/20 0.47
RAB9A P51151 3/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 5/20 0.43
MAPK1 P28482 3/20 0.43
KDM4E B2RXH2 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 5/20 0.43
RPS6KA3 P51812 1/20 0.43
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
METAP2 P50579 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6997403 0.74 NPC1 (0.55) NPC1LMNAHTTTP53GAA
SCHEMBL6993062 0.73 MAPT (0.59) NPC1TP53RAB9AKDM4EKMT2A
SCHEMBL6994754 0.69 NPC1 (0.60) NPC1LMNAHTTTP53GAA
SCHEMBL13153595 0.69 NPC1 (0.51) NPC1LMNAHTTTP53GAA
SCHEMBL27778792 0.68 HTT (0.53) NPC1LMNAHTTTP53GAA
SCHEMBL23242573 0.67 TP53 (0.58) NPC1LMNAHTTTP53GAA
SCHEMBL29800913 0.67 TP53 (0.58) NPC1LMNAHTTTP53GAA
SCHEMBL16404286 0.67 NPC1 (0.70) NPC1LMNAHTTTP53GAA
SCHEMBL651227 0.67 NPC1 (0.70) NPC1LMNAHTTTP53GAA
SCHEMBL8812455 0.67 LMNA (0.75) NPC1LMNAHTTTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
CN-1268949-A Fused thiophene compounds and medical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2000-10-04 CN disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT NPC1 465/4885LMNA 4763/4885HTT 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.